Free Trial

Lexicon Pharmaceuticals (LXRX) Competitors

Lexicon Pharmaceuticals logo
$1.39 -0.05 (-3.47%)
Closing price 04:00 PM Eastern
Extended Trading
$1.42 +0.03 (+1.87%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LXRX vs. CLDX, MNKD, BCRX, NVAX, OPK, DVAX, ZBIO, INVA, GERN, and MYGN

Should you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include Celldex Therapeutics (CLDX), MannKind (MNKD), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), OPKO Health (OPK), Dynavax Technologies (DVAX), Zenas BioPharma (ZBIO), Innoviva (INVA), Geron (GERN), and Myriad Genetics (MYGN). These companies are all part of the "biotechnology" industry.

Lexicon Pharmaceuticals vs. Its Competitors

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Celldex Therapeutics (NASDAQ:CLDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

In the previous week, Celldex Therapeutics had 4 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 5 mentions for Celldex Therapeutics and 1 mentions for Lexicon Pharmaceuticals. Celldex Therapeutics' average media sentiment score of 0.39 beat Lexicon Pharmaceuticals' score of 0.38 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lexicon Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Celldex Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 13.9% of Lexicon Pharmaceuticals shares are held by insiders. Comparatively, 4.4% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Lexicon Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Lexicon Pharmaceuticals has a net margin of -206.43% compared to Celldex Therapeutics' net margin of -3,446.88%. Celldex Therapeutics' return on equity of -27.61% beat Lexicon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lexicon Pharmaceuticals-206.43% -83.63% -42.22%
Celldex Therapeutics -3,446.88%-27.61%-26.20%

Lexicon Pharmaceuticals presently has a consensus target price of $3.23, suggesting a potential upside of 132.01%. Celldex Therapeutics has a consensus target price of $44.20, suggesting a potential upside of 65.42%. Given Lexicon Pharmaceuticals' higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Celldex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lexicon Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29
Celldex Therapeutics
2 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.55

Celldex Therapeutics has lower revenue, but higher earnings than Lexicon Pharmaceuticals. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexicon Pharmaceuticals$31.08M16.25-$200.40M-$0.33-4.21
Celldex Therapeutics$7.02M252.77-$157.86M-$3.01-8.88

Summary

Celldex Therapeutics beats Lexicon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Lexicon Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LXRX vs. The Competition

MetricLexicon PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$523.29M$3.47B$6.18B$10.67B
Dividend YieldN/A2.24%5.72%4.86%
P/E Ratio-4.218.4620.9823.05
Price / Sales16.25463.44582.11126.64
Price / CashN/A45.5937.1261.42
Price / Book3.4810.2912.246.43
Net Income-$200.40M-$52.53M$3.33B$276.63M
7 Day Performance-9.15%-1.46%-1.46%-2.60%
1 Month Performance19.83%9.70%5.03%0.31%
1 Year Performance-28.35%11.69%61.45%30.63%

Lexicon Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LXRX
Lexicon Pharmaceuticals
2.3744 of 5 stars
$1.39
-3.5%
$3.23
+132.0%
-26.2%$523.29M$31.08M-4.21140
CLDX
Celldex Therapeutics
1.5482 of 5 stars
$27.13
+1.3%
$43.78
+61.4%
-2.7%$1.80B$5.79M-9.01150News Coverage
Analyst Forecast
MNKD
MannKind
3.6204 of 5 stars
$5.10
+4.5%
$10.86
+112.9%
-16.8%$1.56B$301.74M46.37400Analyst Forecast
BCRX
BioCryst Pharmaceuticals
4.3795 of 5 stars
$7.04
-2.5%
$16.30
+131.5%
-7.0%$1.48B$450.71M-39.11530
NVAX
Novavax
4.0406 of 5 stars
$8.62
+3.5%
$12.33
+43.1%
-15.3%$1.40B$682.16M3.781,990News Coverage
OPK
OPKO Health
4.0523 of 5 stars
$1.51
flat
$2.63
+73.8%
+2.1%$1.20B$713.10M-6.042,997News Coverage
DVAX
Dynavax Technologies
4.2421 of 5 stars
$10.01
+0.5%
$24.33
+143.1%
-7.8%$1.17B$277.25M-21.76350News Coverage
ZBIO
Zenas BioPharma
2.1509 of 5 stars
$26.54
-0.2%
$38.33
+44.4%
N/A$1.12B$15M-7.48N/A
INVA
Innoviva
4.4938 of 5 stars
$16.94
-2.4%
$37.60
+122.0%
-12.3%$1.07B$370.23M54.65100News Coverage
GERN
Geron
2.7624 of 5 stars
$1.27
-3.1%
$3.79
+198.1%
-67.8%$810.29M$76.99M-9.7770
MYGN
Myriad Genetics
3.6492 of 5 stars
$7.84
+4.5%
$12.45
+58.9%
-64.2%$729.43M$837.60M-1.832,700

Related Companies and Tools


This page (NASDAQ:LXRX) was last updated on 10/22/2025 by MarketBeat.com Staff
From Our Partners